PortfoliosLab logoPortfoliosLab logo
LXRX vs. IPSC
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

LXRX vs. IPSC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Lexicon Pharmaceuticals, Inc. (LXRX) and Century Therapeutics, Inc. (IPSC). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

The year-to-date returns for both investments are quite close, with LXRX having a 100.87% return and IPSC slightly higher at 103.06%.


LXRX

1D
-1.28%
1M
-0.43%
6M
99.14%
YTD
100.87%
1Y
115.89%
3Y*
5.99%
5Y*
-8.18%
10Y*
-17.59%
ALL TIME*
-14.75%

IPSC

1D
-7.76%
1M
-16.87%
6M
6.32%
YTD
103.06%
1Y
279.77%
3Y*
-12.55%
5Y*
-41.37%
10Y*
ALL TIME*
-35.80%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$1.42M$2.12M$2.88M
$6.18M$6.21M$7.76M

LXRX vs. IPSC - Yearly Performance Comparison


2026 (YTD)20252024202320222021
LXRX
Lexicon Pharmaceuticals, Inc.
100.87%55.72%-51.73%-19.90%-51.52%-16.88%
IPSC
Century Therapeutics, Inc.
103.06%-1.50%-69.58%-35.28%-67.65%-18.67%

Correlation

The correlation between LXRX and IPSC is 0.28, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.28

Correlation (3Y)
Balances recent behavior with more history.

0.32

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.31

Correlation (All Time)
Calculated using the full available price history since Jun 18, 2021

0.30

Fundamentals

Market Cap

LXRX:

$1.03B

IPSC:

$174.87M

EPS

LXRX:

-$0.07

IPSC:

-$0.88

PB Ratio

LXRX:

4.56

IPSC:

1.48

Total Revenue (TTM)

LXRX:

$69.64M

IPSC:

$0.00

Gross Profit (TTM)

LXRX:

$69.00M

IPSC:

-$9.88M

EBITDA (TTM)

LXRX:

-$20.38M

IPSC:

-$103.02M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

LXRX vs. IPSC — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

LXRX
LXRX Risk / Return Rank: 8585
Overall Rank
LXRX Sharpe Ratio Rank: 8585
Sharpe Ratio Rank
LXRX Sortino Ratio Rank: 8484
Sortino Ratio Rank
LXRX Omega Ratio Rank: 8181
Omega Ratio Rank
LXRX Calmar Ratio Rank: 8989
Calmar Ratio Rank
LXRX Martin Ratio Rank: 8686
Martin Ratio Rank

IPSC
IPSC Risk / Return Rank: 9696
Overall Rank
IPSC Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
IPSC Sortino Ratio Rank: 9595
Sortino Ratio Rank
IPSC Omega Ratio Rank: 9393
Omega Ratio Rank
IPSC Calmar Ratio Rank: 9898
Calmar Ratio Rank
IPSC Martin Ratio Rank: 9696
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

LXRX vs. IPSC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Lexicon Pharmaceuticals, Inc. (LXRX) and Century Therapeutics, Inc. (IPSC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


LXRXIPSCDifference
Sharpe ratioReturn per unit of total volatility

-1.30

Sortino ratioReturn per unit of downside risk

-1.22

Omega ratioGain probability vs. loss probability

1.27

1.42

-0.15

Calmar ratioReturn relative to maximum drawdown

3.42

7.32

-3.90

Martin ratioReturn relative to average drawdown

7.67

14.90

-7.23

LXRX vs. IPSC - Sharpe Ratio Comparison

The current LXRX Sharpe Ratio is 1.49, which is lower than the IPSC Sharpe Ratio of 2.79. The chart below compares the historical Sharpe Ratios of LXRX and IPSC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

LXRX vs. IPSC - Drawdown Comparison

The maximum LXRX drawdown since its inception was -99.91%, roughly equal to the maximum IPSC drawdown of -98.78%. Use the drawdown chart below to compare losses from any high point for LXRX and IPSC.


Loading charts...

Drawdown Indicators


LXRXIPSCDifference

Max Drawdown

Largest peak-to-trough decline

-99.91%

-98.78%

-1.13%

Max Drawdown (1Y)

Largest decline over 1 year

-34.09%

-36.98%

+2.89%

Max Drawdown (3Y)

Largest decline over 3 years

-91.83%

-92.68%

+0.85%

Max Drawdown (5Y)

Largest decline over 5 years

-95.25%

-98.78%

+3.53%

Max Drawdown (10Y)

Largest decline over 10 years

-98.48%

Current Drawdown

Current decline from peak

-99.30%

-93.67%

-5.63%

Average Drawdown

Average peak-to-trough decline

-93.30%

-80.81%

-12.49%

Ulcer Index

Depth and duration of drawdowns from previous peaks

15.17%

18.14%

-2.97%

Volatility

LXRX vs. IPSC - Volatility Comparison

The current volatility for Lexicon Pharmaceuticals, Inc. (LXRX) is 13.63%, while Century Therapeutics, Inc. (IPSC) has a volatility of 16.98%. This indicates that LXRX experiences smaller price fluctuations and is considered to be less risky than IPSC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


LXRXIPSCDifference

Volatility (1M)

Calculated over the trailing 1-month period

13.63%

16.98%

-3.35%

Volatility (6M)

Calculated over the trailing 6-month period

53.49%

51.48%

+2.01%

Volatility (1Y)

Calculated over the trailing 1-year period

78.14%

97.17%

-19.03%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

97.90%

83.40%

+14.50%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

97.38%

83.64%

+13.74%

Dividends

LXRX vs. IPSC - Dividend Comparison

Neither LXRX nor IPSC has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

LXRX vs. IPSC - Financials Comparison

This section allows you to compare key financial metrics between Lexicon Pharmaceuticals, Inc. and Century Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


LXRX and IPSC have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IPSC has higher volatility (16.98%) compared to LXRX (13.63%). In terms of maximum drawdown, LXRX dropped -99.91% vs IPSC's -98.78%.

IPSC currently has the higher Sharpe Ratio (2.79 vs 1.49), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for LXRX and IPSC

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer